{"id":"flot-chemotherapy","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Neutropenia"},{"rate":"30-50","effect":"Anemia"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"50-70","effect":"Nausea and vomiting"},{"rate":"30-50","effect":"Diarrhea"},{"rate":"20-40","effect":"Peripheral neuropathy"},{"rate":"40-60","effect":"Fatigue"},{"rate":"20-30","effect":"Mucositis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FLOT combines fluorouracil (5-FU), leucovorin, oxaliplatin, and docetaxel to attack cancer cells through multiple mechanisms: 5-FU inhibits thymidylate synthase and incorporates into RNA/DNA; oxaliplatin creates DNA cross-links; and docetaxel stabilizes microtubules to prevent cell division. The combination provides synergistic cytotoxic effects across different phases of the cell cycle.","oneSentence":"FLOT is a combination chemotherapy regimen that uses four cytotoxic agents to inhibit cancer cell division and induce apoptosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:47.994Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric and gastroesophageal junction adenocarcinoma"},{"name":"Metastatic gastric cancer"}]},"trialDetails":[{"nctId":"NCT07001748","phase":"PHASE2, PHASE3","title":"Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2025-08-19","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis","enrollment":148},{"nctId":"NCT07069712","phase":"PHASE2","title":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-17","conditions":"Gastroesophageal Adenocarcinoma","enrollment":100},{"nctId":"NCT05733689","phase":"PHASE1","title":"Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-06-27","conditions":"Gastroesophageal Adenocarcinoma","enrollment":20},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT04882241","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":120},{"nctId":"NCT06279130","phase":"PHASE2, PHASE3","title":"Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-01-29","conditions":"Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid Tumors","enrollment":133},{"nctId":"NCT06078709","phase":"PHASE2","title":"Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-11-20","conditions":"Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8","enrollment":99},{"nctId":"NCT05567835","phase":"PHASE2","title":"A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2024-03-06","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":3},{"nctId":"NCT07400315","phase":"PHASE2","title":"First-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Dual Immunotherapy Combined With Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-03-01","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":64},{"nctId":"NCT07359443","phase":"PHASE1","title":"Combination of Chemotherapy and Adaptive MR-Guided Radiotherapy to Improve Outcomes in Patients With Esophageal Adenocarcinoma","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2025-05-21","conditions":"Esophageal Adenocarcinoma, Esophageal Adenocarcinoma (EAC), Adenocarcinoma - Gastroesophageal Junction (GEJ)","enrollment":39},{"nctId":"NCT06967987","phase":"PHASE2","title":"Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b","status":"WITHDRAWN","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2026-01-01","conditions":"Gastric and Gastro-oesophageal Junction (GEJ) Adenocarcinomas, Overexpression FGFR2b","enrollment":""},{"nctId":"NCT07313579","phase":"","title":"Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer","status":"RECRUITING","sponsor":"Ukrainian Society of Clinical Oncology","startDate":"2025-12-01","conditions":"Gastric Cancer (GC), HIPEC, Peritoneal Metastases From Gastric Cancer","enrollment":200},{"nctId":"NCT04028167","phase":"PHASE2","title":"Induction FLOT With CROSS CRT for Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2020-04-08","conditions":"Adenocarcinoma Esophagus, Adenocarcinoma of the Gastroesophageal Junction","enrollment":40},{"nctId":"NCT07283848","phase":"PHASE2","title":"Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2026-02-01","conditions":"Adenocarcinoma Stomach, Adenocarcinoma Gastroesophageal Junction","enrollment":""},{"nctId":"NCT04592913","phase":"PHASE3","title":"Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-11-17","conditions":"Gastrointestinal Neoplasms, Esophagogastric Junction","enrollment":957},{"nctId":"NCT06161818","phase":"PHASE2","title":"Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2025-09-12","conditions":"Esophageal Cancer, Adenocarcinoma of the Esophagus","enrollment":216},{"nctId":"NCT07059299","phase":"PHASE1","title":"A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2025-12-12","conditions":"Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma","enrollment":18},{"nctId":"NCT07101666","phase":"PHASE2","title":"Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-01-31","conditions":"Gastric Cancer","enrollment":20},{"nctId":"NCT07257380","phase":"PHASE2","title":"Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-30","conditions":"Gastric / Gastroesophageal Junction Adenocarcinoma","enrollment":90},{"nctId":"NCT07257575","phase":"PHASE2","title":"A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2025-01-05","conditions":"Gastric Cancer Stage III","enrollment":138},{"nctId":"NCT05836584","phase":"PHASE2","title":"Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-06","conditions":"Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8","enrollment":240},{"nctId":"NCT07222657","phase":"PHASE2","title":"Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-11","conditions":"Esophageal Adenocarcinoma, Esophageal Cancer","enrollment":40},{"nctId":"NCT03505320","phase":"PHASE2","title":"A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-06-29","conditions":"Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer","enrollment":143},{"nctId":"NCT05709574","phase":"PHASE2","title":"Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2023-04-20","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":10},{"nctId":"NCT07018570","phase":"PHASE2","title":"An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2025-07-24","conditions":"Gastroesophageal Junction (GEJ) Adenocarcinoma","enrollment":26},{"nctId":"NCT07098104","phase":"","title":"A Benefit Population Atlas of nICT Versus nCT for LAGC","status":"COMPLETED","sponsor":"Cheng Chen","startDate":"2019-11-01","conditions":"Gastric Cancer","enrollment":291},{"nctId":"NCT03421288","phase":"PHASE2","title":"Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2018-09-14","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":677},{"nctId":"NCT03636893","phase":"PHASE2","title":"Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2018-08-24","conditions":"Gastric Cancer, Chemotherapy Effect","enrollment":74},{"nctId":"NCT06906887","phase":"PHASE2","title":"PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2025-06-17","conditions":"Esophageal Cancer, Oesophageal Cancer, GastroEsophageal Cancer","enrollment":50},{"nctId":"NCT05504720","phase":"PHASE2","title":"Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2023-02-13","conditions":"Esophagogastric Adenocarcinoma","enrollment":31},{"nctId":"NCT06440811","phase":"","title":"Efficacy and Safety of Neoadjuvant Nivolumab Plus SOX Versus Nivolumab Plus FLOT in Patients With HER2-negative Gastric and Gastroesophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2021-01-01","conditions":"Immune-related Adverse Event, Chemotherapeutic Toxicity, Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":120},{"nctId":"NCT06784765","phase":"NA","title":"Preventive Use of PIPAC in Locally Advanced Gastric Cancer.","status":"RECRUITING","sponsor":"National Research Oncology and Transplantology Center, Kazakhstan","startDate":"2025-01-15","conditions":"Gastric Cancer","enrollment":160},{"nctId":"NCT06028737","phase":"PHASE2, PHASE3","title":"Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"Ukrainian Society of Clinical Oncology","startDate":"2025-03-25","conditions":"Gastric Cancer, Stomach Cancer, GastroEsophageal Cancer","enrollment":150},{"nctId":"NCT06933966","phase":"PHASE2","title":"Evaluation of Efficacy and Safety De-escalation Versus Standard Adjuvant Chemotherapy in Patients With Low Risk Localized Gastroesophageal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Centre Leon Berard","startDate":"2025-09-01","conditions":"Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma, Non Metastatic Disease","enrollment":120},{"nctId":"NCT01924819","phase":"PHASE2, PHASE3","title":"Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2009-09","conditions":"Gastric Cancer","enrollment":574},{"nctId":"NCT05296005","phase":"PHASE1","title":"Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers","status":"WITHDRAWN","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2025-12-31","conditions":"Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8","enrollment":""},{"nctId":"NCT04162665","phase":"PHASE2","title":"Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2020-02-14","conditions":"Gastric Adenocarcinoma","enrollment":4},{"nctId":"NCT04375605","phase":"PHASE3","title":"Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitätsmedizin Mannheim","startDate":"2020-06-03","conditions":"Gastroesophageal Junction Adenocarcinoma","enrollment":342},{"nctId":"NCT02578368","phase":"PHASE3","title":"Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction","status":"COMPLETED","sponsor":"Krankenhaus Nordwest","startDate":"2016-02","conditions":"Gastric Cancer","enrollment":183},{"nctId":"NCT06642506","phase":"","title":"Oncometabolome and MALDI-MSI in Upper GI Carcinomas - Chemosensitivity in Esophageal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2024-10-06","conditions":"Esophagus Adenocarcinoma, Esophagus Cancer, Metabolome","enrollment":20},{"nctId":"NCT06684158","phase":"PHASE2","title":"Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-11-30","conditions":"GC/GEJC","enrollment":70},{"nctId":"NCT06681298","phase":"PHASE2","title":"A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With Trastuzumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"xiaohua li","startDate":"2024-05-01","conditions":"Adenocarcinoma of the Esophagogastric Junction, Perioperative Period","enrollment":36},{"nctId":"NCT03979131","phase":"PHASE2","title":"Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vall d'Hebron Institute of Oncology","startDate":"2019-08-22","conditions":"Gastroesophageal Junction Adenocarcinoma, Stomach Neoplasms","enrollment":40},{"nctId":"NCT04937738","phase":"PHASE2","title":"Perioperative Chemotherapy in Gastric Cancer","status":"TERMINATED","sponsor":"Ukrainian Society of Clinical Oncology","startDate":"2021-07-21","conditions":"Gastric Cancer","enrollment":69},{"nctId":"NCT06459921","phase":"PHASE2","title":"Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2024-12-01","conditions":"Neoadjuvant Chemotherapy, Sintilimab, Locally Advanced Gastric Cancer","enrollment":200},{"nctId":"NCT05715931","phase":"PHASE2","title":"Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Yu jiren","startDate":"2023-02-28","conditions":"Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, HER2-positive Gastric Cancer","enrollment":30},{"nctId":"NCT01404156","phase":"PHASE2, PHASE3","title":"Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma","status":"COMPLETED","sponsor":"Dr. Gordon Buduhan","startDate":"2015-09","conditions":"Esophageal Cancer, Adenocarcinoma, Esophageal, Adenocarcinoma, Gastroesophageal Junction","enrollment":29},{"nctId":"NCT03647969","phase":"PHASE2","title":"Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2018-11-07","conditions":"Adenocarcinoma of the Stomach, GastroEsophageal Cancer","enrollment":262},{"nctId":"NCT06253650","phase":"PHASE2","title":"Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2024-03-01","conditions":"Gastric Cancer, HER2-positive Gastric Cancer","enrollment":46},{"nctId":"NCT06411171","phase":"PHASE3","title":"Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:","status":"NOT_YET_RECRUITING","sponsor":"xiaohua li","startDate":"2024-06-01","conditions":"Gastroesophageal Junction Cancer","enrollment":36},{"nctId":"NCT04878783","phase":"","title":"Radiomics and Molecular Expression Predictive Model for Esophago-Gastric Junction and Gastric Cancer TRG","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Roma La Sapienza","startDate":"2019-12-20","conditions":"Gastric Cancer, Adenocarcinoma of the Stomach","enrollment":138},{"nctId":"NCT02509286","phase":"PHASE3","title":"Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Schleswig-Holstein","startDate":"2016-01","conditions":"Esophageal Adenocarcinoma (UICC TNM7), Adenocarcinoma of the Esophagogastric Junction","enrollment":438},{"nctId":"NCT02735239","phase":"PHASE1, PHASE2","title":"Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2016-06-24","conditions":"Esophageal Cancer","enrollment":73},{"nctId":"NCT04062656","phase":"PHASE2","title":"Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG","status":"UNKNOWN","sponsor":"University Hospital, Essen","startDate":"2019-09-26","conditions":"Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction","enrollment":21},{"nctId":"NCT04597294","phase":"PHASE3","title":"Prophylactic Preoperative HIPEC in Advanced Gastric Cancer at High Risk of Peritoneal Recurrence","status":"RECRUITING","sponsor":"Jagiellonian University","startDate":"2021-08-01","conditions":"Gastric Cancer","enrollment":600},{"nctId":"NCT06235164","phase":"","title":"The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer","status":"UNKNOWN","sponsor":"Fujian Medical University","startDate":"2019-01-01","conditions":"Locally Advanced Gastric Cancer","enrollment":585},{"nctId":"NCT03607656","phase":"PHASE2, PHASE3","title":"The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2018-06-08","conditions":"Gastric Cancer Stage IIIB, Gastric Cancer Stage IIIC","enrollment":270},{"nctId":"NCT05960955","phase":"PHASE2","title":"Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2023-11-13","conditions":"Resectable Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":90},{"nctId":"NCT05264896","phase":"PHASE3","title":"Perioperative FLOT vs Adjuvant XELOX for CA Stomach","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2022-03-21","conditions":"Cancer of Stomach, Adenocarcinoma","enrollment":110},{"nctId":"NCT03399071","phase":"PHASE2","title":"Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer","status":"UNKNOWN","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2017-07-31","conditions":"Gastric Adenocarcinoma, Oesophageal Adenocarcinoma","enrollment":44},{"nctId":"NCT01726452","phase":"PHASE3","title":"NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2013-01-24","conditions":"Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Oesophago-gastric Junction, Oesophageal Tumours","enrollment":377},{"nctId":"NCT04384601","phase":"PHASE3","title":"Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2021-09","conditions":"Gastric Cancer, Neoadjuvant Chemotherapy","enrollment":246},{"nctId":"NCT04393584","phase":"PHASE2, PHASE3","title":"FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2019-01-29","conditions":"Stomach Neoplasms, Gastrointestinal Neoplasms, Docetaxel","enrollment":538},{"nctId":"NCT02128243","phase":"PHASE2","title":"Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2014-09","conditions":"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastric Neoplasm, Gastroesophageal Junction Adenocarcinoma","enrollment":242},{"nctId":"NCT04354662","phase":"PHASE2","title":"Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2019-09-26","conditions":"Gastric Cancer","enrollment":35},{"nctId":"NCT04595929","phase":"NA","title":"Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt-","status":"RECRUITING","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2020-02-10","conditions":"Peritoneal Carcinomatosis, Gastric Cancer","enrollment":304},{"nctId":"NCT03646591","phase":"","title":"Feasibility and Safety of Neoadjuvant Chemotherapy (FLOT ) for Gastric Cancer Patients in China","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2017-11-15","conditions":"Chemotherapy Effect","enrollment":10},{"nctId":"NCT03606928","phase":"PHASE1, PHASE2","title":"mFLOT Chemotherapy as First-line Treatment in GC","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2018-07-01","conditions":"Gastric Cancer","enrollment":18},{"nctId":"NCT03961841","phase":"PHASE3","title":"Perioperative Combination Chemotherapy Versus Chemoradiation for Locally Advanced EGJ Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2020-06","conditions":"Esophagogastric Junction Disorder, Neoplasms","enrollment":900},{"nctId":"NCT03451942","phase":"PHASE2","title":"The FLOT Regimen Conversion Therapy of Adenocarcinoma of the Stomach / Gastroesophageal","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2018-02-05","conditions":"Adenocarcinoma of the Stomach / Gastroesophageal","enrollment":112},{"nctId":"NCT01932580","phase":"PHASE2","title":"Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma","status":"COMPLETED","sponsor":"McGill University","startDate":"2013-08","conditions":"Gastric Adenocarcinoma, Esophageal Adenocarcinoma","enrollment":10},{"nctId":"NCT01160419","phase":"PHASE2","title":"Multicenter Study to Perioperative Chemotherapy for Resectable Adenocarcinoma in Gastric Cancer","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2009-12","conditions":"Gastric Cancer","enrollment":49}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":86,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["FLOT"],"phase":"phase_3","status":"active","brandName":"FLOT chemotherapy","genericName":"FLOT chemotherapy","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FLOT is a combination chemotherapy regimen that uses four cytotoxic agents to inhibit cancer cell division and induce apoptosis. Used for Gastric and gastroesophageal junction adenocarcinoma, Metastatic gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}